Phaseline

Companies › Alpha Cognition

Alpha Cognition: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Neurology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Benzgalantamine
Acetylcholinesterase inhibitor
ACHEPhase 4Alzheimer DiseaseApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07633470BenzgalantaminePhase 4Alzheimer DiseaseNeurologyApr 2027

From the company's SEC filings

Cash of $41m on 2026-06-30; operating cash outflow about $38m a year; runway about 13 months at that burn, to Aug 2027

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ACHE (1)

Companies with the same targets

Supernus Pharmaceuticals Wanbangde Pharmaceutical Group Inventage Lab.

Companies built like this

Wanbangde Pharmaceutical Group Immunic NervGen Pharma Satellos Bioscience Coya Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.